Dissemination of carcinoma cells requires the pericellular degradation of the extracellular matrix, which is mediated by membrane type 1-matrix metalloproteinase (MT1-MMP). In this article, we report a co-up-regulation and colocalization of MT1-MMP and atypical protein kinase C iota (aPKCι) in hormone receptor-negative breast tumors in association with a higher risk of metastasis. Silencing of aPKC in invasive breast-tumor cell lines impaired the delivery of MT1-MMP from late endocytic storage compartments to the surface and inhibited matrix degradation and invasion. We provide evidence that aPKCι, in association with MT1-MMP-containing endosomes, phosphorylates cortactin, which is present in F-actin-rich puncta on MT1-MMP-positive endosomes and regulates cortactin association with the membrane scission protein dynamin-2. Thus, cell line-based observations and clinical data reveal the concerted activity of aPKC, cortactin, and dynamin-2, which control the trafficking of MT1-MMP from late endosome to the plasma membrane and play an important role in the invasive potential of breast-cancer cells.
Dissemination of carcinoma cells requires the pericellular degradation of the extracellular matrix, which is mediated by membrane type 1-matrix metalloproteinase (MT1-MMP). In this article, we report a co-up-regulation and colocalization of MT1-MMP and atypical protein kinase C iota (aPKCι) in hormone receptor-negative breast tumors in association with a higher risk of metastasis. Silencing of aPKC in invasive breast-tumor cell lines impaired the delivery of MT1-MMP from late endocytic storage compartments to the surface and inhibited matrix degradation and invasion. We provide evidence that aPKCι, in association with MT1-MMP-containing endosomes, phosphorylates cortactin, which is present in F-actin-rich puncta on MT1-MMP-positive endosomes and regulates cortactin association with the membrane scission protein dynamin-2. Thus, cell line-based observations and clinical data reveal the concerted activity of aPKC, cortactin, and dynamin-2, which control the trafficking of MT1-MMP from late endosome to the plasma membrane and play an important role in the invasive potential of breast-cancer cells.
membrane traffic | actin cytoskeleton | multi-vesicular body | MMP14 M etastasis-the process by which cells from a primary tumor invade local tissues and disseminate to distant sitesmarks the transition from a benign tumor to a lethal, malignant cancer. One intrinsic property of metastatic tumor cells that allows them to breach tissue barriers is their ability to degrade the proteins of the extracellular matrix (ECM). This remodeling of the ECM by cancer cells depends on matrix-degrading proteases, including matrix metalloproteinases (MMPs) (1, 2) . Although secreted MMPs have been implicated in cancer for several decades, it is more recently that a subgroup of membraneanchored MMPs, including membrane type 1 (MT1)-MMP, have been recognized as important proteases involved in dissemination of tumor cells and cancer progression (3) (4) (5) (6) (7) .
Membrane type 1-matrix metalloproteinase (MT1-MMP) is up-regulated in human cancers, including breast cancers, and it is enriched at the front of invasive lesions (8, 9) . In tumor-derived cells cultured on a flat ECM substratum, such as gelatin or type I collagen, MT1-MMP accumulates in specialized matrix-degrading plasma-membrane domains called invadopodia (10) . The current view is that interaction of matrix receptors on the tumorcell surface with components of the ECM leads to assembly of nascent invadopodia containing F-actin and cortactin, which mature into matrix-degrading invadopodia when they accumulate MT1-MMP (11) .
Little is known about how invadopodia form in metastatic cells and how they are endowed with proteolytic activity. In MDA-MB-231 human breast adenocarcinoma cells, newly synthesized MT1-MMP passes through the secretory pathway to reach the plasma membrane where it is then endocytosed (12) . The majority of internalized MT1-MMP is located in a late endocytic compartment from where a fraction recycles to plasma-membrane invadopodia (13) . Various studies, including our own, have identified several components of the exocytic machinery that are required for delivery of MT1-MMP to invadopodia, including cortactin (a regulator of actin dynamics), the exocyst complex (required for docking of transport vesicles), and vesicle-associated membrane protein 7 (VAMP7) (a late endosome v-SNARE protein involved in vesicle fusion) (10, (13) (14) (15) (16) . Although these findings provide important insights into how MT1-MMP is delivered to the invadopodial plasma membrane, the mechanisms underlying the formation of MT1-MMP transport intermediates from late endocytic compartments remain largely unexplored.
Atypical protein kinase C (aPKC) comprises a branch of the serine/threonine PKC superfamily consisting of two isoforms, aPKCς and aPKCι, that are distinct from the typical, diacylglycerol-regulated isoforms (17) . aPKCζ/ι are activated mainly by components of the PAR complex, Cdc42 and Par-3, and play a critical role in the formation of epithelial cell-cell junctions and the development of apico-basal polarity in mammalian epithelial cells (18) . Previously, we reported the role of an aPKCζ/ι-exocyst complex in signaling at the leading edge of
Significance
We characterize a mechanism through which the polarity protein atypical PKCι controls invasion and matrix remodeling by tumor cells by regulating endosome-to-plasma membrane traffic of the membrane type 1-matrix metalloproteinase (MT1-MMP) in breast-cancer cells. Further analysis shows that atypical PKCι and MT1-MMP are co-up-regulated in hormone receptor-negative breast tumors in association with higher risk of metastasis. These findings provide previously unidentified avenues for the design of therapeutic interventions.
migrating cells, so controlling paxillin phosphorylation and regulating focal adhesion dynamics (19) . In addition, several lines of evidence implicate aPKCζ/ι in cancer: aPKCς is required for epidermal growth factor-induced chemotaxis of human breast-cancer cells (20) , and aPKCζ/ι promotes matrix degradation by Src-transformed mouse NIH 3T3 fibroblasts (21) . Moreover, aPKCι expression is up-regulated in various cancers, including breast cancer, and correlates with poor prognosis (22, 23) . The ability of aPKCζ/ι to control both cell polarity and the migration of cells makes it a prime candidate for a role in tumor progression and metastasis although the specific functions of aPKCζ/ι in metastatic cells are currently only poorly understood.
Here, we report an up-regulation and relocalization of MT1-MMP and aPKCι in breast-tumor samples associated with a high risk of metastasis. We found that silencing of aPKCζ/ι in human breast adenocarcinoma cell lines impairs ECM degradation and invasion of the cells into different reconstituted 3D matrix environments. These functional effects of aPKCζ/ι silencing correlate with defects in cortactin phosphorylation and distribution and dynamin-2 (dyn-2) recruitment and function on MT1-MMP-containing endosomes, resulting in impaired delivery of MT1-MMP to the invadopodial plasma membrane. This study thus identifies a previous unidentified coordinated function for aPKCζ/ι, cortactin, and dyn-2 in the control of MT1-MMP trafficking from late endosomes to the plasma membrane during breast-tumor cell invasion, providing a rationale for the design of therapeutic interventions.
Results

Co-Up-Regulation of MT1-MMP and aPKCι mRNAs Is Associated with
Adverse Clinical Outcomes in Breast Cancer. In previous studies, we implicated the exocyst complex in MT1-MMP trafficking to invadopodia in MDA-MB-231 breast-tumor cells (15) and identified a coordinated function of the exocyst complex and aPKCζ/ι in migrating cells (19) . MT1-MMP and aPKCι are overexpressed in various cancers, including breast cancers, and up-regulation is associated with poor prognosis (8, 9, 22, 24) . These data suggested the possible interplay between MT1-MMP and aPKCζ/ι in the invasive program of breast-tumor cells. Expression of MT1-MMP and 11 aPKCζ/ι family members was investigated by qRT-PCR analysis in breast-tumor samples from 458 patients with unilateral invasive breast tumors and known long-term outcome (Table S1 ). MT1-MMP expression correlated most with aPKCι mRNA (r = +0.556, P < 10 −7 ) ( Table 1) . We looked for correlations between aPKCι and MT1-MMP mRNA status and standard clinicopathological and biological factors in this cohort. About one third of breast tumors tested (153/458) showed aPKCι mRNA overexpression (a greater than threefold increase compared with normal tissues), and 23.3% (107/458) showed MT1-MMP mRNA overexpression (Table S1 ). In the tumor group that overexpressed both aPKCι and MT1-MMP, we saw a statistically significant association with histopathological grade III (P = 0.0041), estrogen receptor (ER)-negative (P = 0.0014), and progesterone receptor (PR)-negative (P = 0.001) status, as well as with the molecular subtype (P = 0.003) (Table S1 ). Of note, 24.6% (17/69) of triple-negative breast cancers (ER − PR − HER2 − ), a type of aggressive and highly proliferative tumors, overexpressed MT1-MMP and aPKCι vs. 12.8% (50/389) for the other subtypes (P = 0.011). Furthermore, by combining aPKCι and MT1-MMP mRNA expression status, we identified four distinct prognostic groups with significantly different metastasis-free survival (MFS) curves (P = 0.008) (Fig. 1A) . The patients with the poorest prognosis had both aPKCι and MT1-MMP mRNA overexpression whereas those with the best prognosis had normal aPKCι and MT1-MMP mRNA levels. To investigate changes in protein levels and localization of MT1-MMP and aPKCι during breast-tumor progression, a human tissue microarray (TMA) of 68 breast tumors representative of the four main molecular subtypes (Experimental Procedures) was analyzed by immunohistocytochemistry (IHC), on consecutive sections (25) (Dataset S1 and Fig. 1 Fig. S1 A and B, and Fig. 1D ). These data demonstrate a positive correlation between aPKCι and MT1-MMP expression in hormone receptor-negative subtypes of breast carcinomas at both the mRNA and protein levels.
aPKCι staining was restricted to the apical surface of normal breast epithelial cells lining the lumen of the duct whereas, in tumor cells, overexpressed aPKCι lost its apical localization (Fig.  1B and Fig. S1C ) and showed a predominant unpolarized distribution at cell-cell contacts and cytoplasmic granules in the majority of the tumors (Fig. 1B and Fig. S1 D and E). There was little or no aPKCι staining in the stroma. MT1-MMP was laterally localized in luminal epithelial cells in normal tissues and also expressed in myoepithelial cells (Fig. 1C and Fig. S1C ). MT1-MMP distribution was predominantly unpolarized in cancer cells in overexpressing tumors (Fig. 1C and Fig. S1C ), with both a strong cell-cell contact association and a granular cytoplasmic distribution (Fig. 1C and Fig. S1 D and E) . Thus, in contrast to their distinct localization at separate plasma-membrane domains of normal luminal breast epithelial cells, aPKCι and MT1-MMP significantly codistributed at cell-cell contacts and cytoplasmic granules, including in hormone receptor-negative tumors. These findings correlating up-regulation of aPKCι and MT1-MMP during breast-tumor progression indicate a poor prognosis for these combined markers. (26) . Silencing of MT1-MMP expression strongly diminished invadopodial degradation of gelatin ( Fig. 2 A and B) (10, 15). We investigated whether Table 1 . Correlation using the Spearman's rank correlation test between 11 genes of the PKC family and MT1-MMP mRNA expression in human breast cancer
Expression of genes encoding PKCs and MT1-MMP was analyzed by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) of 458 mRNA tumor samples. Very low levels of mRNA encoding PKCγ were detectable but not reliably quantifiable by RT-qPCR assays using the fluorescence SYBR green methodology (cycle threshold > 35). NS, not significant. *P value of Spearman rank correlation test. In bold type, significant P values.
aPKCζ/ι played a role in MT1-MMP-dependent matrix proteolysis by silencing both aPKCζ and aPKCι in these cell lines using two independent pairs of siRNAs ( Fig. 2 A We further assessed the effect of aPKCζ/ι silencing on MDA-MB-231 cell invasion across a thick layer of Matrigel and on invasive migration through fibrous type I collagen because MT1-MMP is required for invasion in these environments (13, 27) . Double silencing of aPKCζ and aPKCι impaired invasion in Matrigel to a similar extent to silencing of MT1-MMP itself ( (53) . n, the number of tumors analyzed. *P < 0.05; ***P < 0.001; ns, non significant compared with normal adjacent tissues (χ 2 test). Note that intensity scores of MT1-MMP expression in luminal A+B tumors are inferior to normal tissues. Data are mean invasion area in type I collagen at T2 normalized to the mean invasion area at T0 ± SEM (n = 3 independent experiments; 15-20 spheroids were analyzed for each cell population). ***P < 0.001. F). These data indicate that aPKCζ/ι is required for MT1-MMPdependent invasion of MDA-MB-231 cells in two different reconstituted matrices that mimic the 3D environment of cancer cells in vivo.
Atypical PKCζ/ι Control MT1-MMP-Containing Endosome Distribution and MT1-MMP Exocytosis. Immunoelectron microscopy of MDA-MB-231 cells stably expressing MT1-MMP-mCherry revealed association of MT1-MMP with the limiting membrane and internal luminal vesicles of vesicular compartments, with morphology typical of multivesicular bodies (Fig. 3A) . These observations are consistent with the predominant association of MT1-MMP with VAMP7-and Rab7-positive late endocytic compartments in MDA-MB-231 cells (13, 16) . Imaging of live cells expressing GFP-aPKCι revealed an association of this protein with ∼32% of MT1-MMP-mCherry-positive vesicles ( Fig. 3B and Fig. S2E) , reminiscent of the colocalization of aPKCι and MT1-MMP on cytoplasmic granular compartments in hormone receptor-negative breast carcinoma (Fig. 1C and Fig. S1E ).
We investigated whether aPKCζ/ι may be required for MT1-MMP trafficking to the plasma membrane. Expression of a constitutively active allele of aPKCι resulted in an ∼1.5-fold increase of the density of MT1-MMP-containing vesicles in the vicinity of the plasma membrane visualized by total interference reflection fluorescence microscopy (TIRFM) (Fig. 3 C and D and Fig.  S2F ). On the contrary, aPKCζ/ι depletion induced a twofold reduction in MT1-MMP-positive endosomes at the plasma membrane (Fig. 3E and Fig. S2G ). The contribution of aPKCζ/ι to MT1-MMP delivery to the invadopodial plasma membrane was assessed by quantifying surface accumulation of MT1-MMP-pHluorin (28); fluorescence of this construct is eclipsed in the acidic environment of the late endosome and rises immediately upon exocytosis and exposure to the extracellular pH (29) . As expected, MT1-MMP-pHluorin accumulated at the level of cortactin-positive invadopodia on the ventral cell surface (Fig.  3F) . Knockdown of aPKCζ/ι led to a 40-60% reduction of plasma-membrane accumulation of MT1-MMP-pHluorin, similar to the effect of cortactin siRNA, which is required for MT1-MMP delivery to invadopodia (10, 14) (Fig. 3G) . All together, these data reveal that aPKCζ/ι controls the polarization of MT1-MMP-positive endosomes to the cell surface and MT1-MMP exocytosis and regulates pericellular matrix remodeling. (Fig. 3F and Fig. S2 C and D) (10, 14) , cortactin also accumulated in the central region of the cell and was dynamically associated with MT1-MMP-containing endosomes (more than 95% of MT1-MMP-positive endosomes harbored at least one cortactin-rich puncta) (Fig. 4A and Movie S1). In addition, Factin and the p34-Arc subunit of Arp2/3 complex, which are components of the cytoskeleton and partner proteins of cortactin, colocalized with cortactin patches on MT1-MMP-containing endosomes in MDA-MB-231 and BT-549 cells (Fig. S3 A-C) . High-resolution structured illumination microscopy revealed the presence of distinct submicrometer-sized cortactin domains associated with MT1-MMP-positive endosomes (Fig. S3D) . Knockdown of aPKCζ/ι induced coalescence of the cortactin domains on MT1-MMP-containing endosomes (Fig. 4A and Fig. S3D ) and a dramatic ∼80% increase of cortactin on MT1-MMP-positive endosomes (Fig. 4B ). These data demonstrate that cortactin associates with F-actin assemblies on MT1-MMP-positive endosomes in an aPKCζ/ι-regulated manner.
The endosomal actin and cortactin cytoskeleton is known to regulate the formation and fission of tubulovesicular transport carriers involved in the recycling of surface proteins within the endocytic pathway (30, 31) . We looked at the dynamic distribution of the late endocytic marker GFP-Rab7, which is associated with MT1-MMP-positive endosomes and colocalizes with endosomal cortactin (Fig. S3E) (32) . By live-cell imaging, we observed the formation of GFP-Rab7-positive tubules emanating from MT1-MMP-containing endosomes and the fission of these tubules (Fig. S3F, Upper) . Silencing of aPKCζ/ι, by contrast, was accompanied by more persistent Rab7-and MT1-MMPcontaining tubular extensions (Fig. S3 E, Right and F, Lower) , suggesting that aPKCζ/ι controls MT1-MMP-containing late endosome membrane remodeling. Cortactin regulates membrane dynamics through its interaction with dyn-2, which is involved in membrane scission and is required for the formation and function of invadopodia (33, 34) . We therefore analyzed the location of endogenous dyn-2 and cortactin by immunolabeling MDA-MB-231 cells stably expressing MT1-MMP-mCherry. This immunolabeling revealed a close apposition of dyn-2 patches with cortactin puncta on ∼90% of MT1-MMP-positive endosomes (Fig. 4C , internal plane). Note that, as expected, dyn-2 associated with clathrin-coated pits on the plasma membrane with partial colocalization with cortactin (Fig. 4C, ventral plane) . When coexpressed with DsRed-cortactin, GFP-dyn-2 colocalized with cortactin domains on vesicular structures in the centralcell region (Fig. 4D and Movie S2). In addition, deletion of the proline-rich domain (ΔPRD) of dyn-2, which mediates its interaction with the SH3 domain of cortactin (33), abolished dyn-2 association with MT1-MMP-containing vesicles (Fig.  S4A) . Reciprocally, expression of a DsRed-cortactin protein lacking the SH3 domain (cortactinΔSH3) resulted in a diffuse cytosolic distribution of GFP-dyn-2 ( Fig. S4B and quantification in Fig. 5C ). These data demonstrate that dyn-2 colocalizes with cortactin on MT1-MMP-containing endosomes and indicate a cortactin-dependent, possibly transient association of dyn-2 with these endosomes.
The observation that loss of aPKCζ/ι activity triggered accumulation of Rab7-and MT1-MMP-positive membrane tubules (Fig. S3 E and F) prompted us to investigate whether accumulation of cortactin on MT1-MMP-containing endosomes in aPKCζ/ι-depleted cells affected dyn-2 recruitment and consequently tubule fission. To do so, we silenced aPKCζ/ι in MDA-MB-231 cells and observed a reduction of GFP-Dyn-2 recruitment associated with DsRed-cortactin patches along with increased endosomal cortactin accumulation ( Fig. 4E and Fig. S4C, internal plane) . Analysis of the intensity ratio of the fluorescence signals from GFP-dyn-2 and DsRed-cortactin in endosomal patches showed that the intensity ratio in aPKCζ/ι-depleted cells was reduced by 60% compared with the controlsiLuc-treated-cells (Fig. 4F) . In contrast, aPKCζ/ι knockdown did not affect the association of Dyn-2 with clathrin-coated pits at the plasma membrane (Fig. S4C, ventral plane) . Thus, we conclude that accumulation of cortactin in the absence of aPKCζ/ι function interferes specifically with Dyn-2 recruitment on MT1-MMP-containing late endosomes. In addition, in agreement with previous findings (34), silencing of dyn-2 in MDA-MB-231 cells correlated with a substantial loss of their ability to degrade the matrix similar to the effect of cortactin knockdown (Fig. 4G) . Accumulation of MT1-MMP-positive vesicles and tubules connected to and extending from MT1-MMP-containing endosomes was visible in Dyn-2-depleted cells (Fig. S4 D and E and Movie S3). Collectively, these data indicate that dyn-2 acts downstream of cortactin and that aPKCζ/ι is required for the formation and function of cortactin-dyn-2 assemblies on multivesicular bodies/ late endosomes, suggesting a mechanism involved in the formation and fission of tubulovesicular carriers from these endosomes.
aPKCζ/ι-Dependent Phosphorylation of Cortactin Controls Its
Association with dyn-2. We then addressed how aPKCζ/ι controls cortactin and dyn-2 association on MT1-MMP-containing endosomes. We tested whether cortactin was a direct substrate for aPKCζ/ι by incubating purified GST-tagged human cortactin in the presence of recombinant human aPKCι. Phosphorylation was detected with antibodies raised against cortactin phosphoSer298, which was recently identified as a phosphorylation site for aPKCζ/ι-related PKD (35, 36) . In higher metazoans, mRNA splicing generates cortactin variants with four, five, or six conserved tandem actin-binding repeats in which repeats 5 and 6 are the most conserved (37) . The cortactin variant used for this study contains five tandem repeats; Ser261 in repeat 5 is highly conserved and equivalent to Ser298 in repeat 6. Recombinant aPKCι induced phosphorylation of recombinant human cortactin (Fig. 5A ). In addition, coexpression of the five repeatcontaining cortactin variant (33) with aPKCι in MDA-MB-231 cells similarly resulted in phosphorylation of cortactin (Fig. 5B) . Thus, our data suggest that Ser261 is directly phosphorylated by aPKCι.
Next, we investigated the consequences of substitution of serine 261 to alanine (nonphosphorylable mutation) or to aspartate (phosphomimetic mutation) on gelatin degradation. Overexpression of cortactin S261A in BT-549 cells led to an ∼50% reduction in matrix degradation whereas cortactin S261D had the opposite stimulatory effect (Fig. S4F) . In addition, similar to the loss of aPKCζ/ι (Fig. 4 E and F) , expression of cortactin-S261A caused drastic and specific depletion of dyn-2 from endosomal patches (Fig. 5C and Fig. S4G ). By contrast, mutation of the extracellular signal-regulated serine/threonine kinase (ERK1/2) phosphorylation sites S405 and S418 of cortactin into alanine did not affect dyn-2 association with endosomes (Fig. 5C ). Overexpression of the phosphomimetic cortactin S261D variant did not affect significantly dyn-2 recruitment on MT1-MMP-containing endosomes (Fig. 5C ), suggesting that aPKCζ/ι-mediated phosphorylation of cortactin may also affect the dynamics of dyn-2 association to MT1-MMP-positive late endosomes. Finally, we observed that, in breast tumors, increased total phosphorylated aPKCι correlated with high cortactin expression and phosphorylation at the aPKCι-specific site in the actin-binding repeats (Fig. 5D) . Together, our data indicate that aPKCι-mediated phosphorylation of cortactin regulates endosomal accumulation of cortactin and its association with dyn-2 to control MT1-MMPpositive endosome dynamics during the invasive program of breasttumor cells.
Discussion
In this study, we report an unprecedented function for aPKCζ/ι in the invasion of breast-tumor cells. Our data show that aPKCζ/ι silencing in two breast-adenocarcinoma cell lines representative of triple-negative breast cancers inhibits MT1-MMP-dependent matrix degradation and tumor-cell invasion, while having no effect on MT1-MMP expression. Instead, aPKCζ/ι controls the trafficking and plasma-membrane targeting of MT1-MMP to invadopodia. In MDA-MB-231 and BT-549 cells, aPKCζ/ι associates partially with cortactin and its binding partners, F-actin and dyn-2, in patches on late endosomes that contain an intracellular reservoir of the transmembrane metalloproteinase MT1-MMP. aPKCζ/ι phosphorylates cortactin directly, and depletion of the kinase interferes with cortactin-dependent recruitment of the membrane scission protein dyn-2, correlating with tubulation of endosomal membranes and impaired trafficking and exocytosis of MT1-MMP to the cell surface. Thus, we conclude that aPKCζ/ι promotes the formation of transport vesicles carrying MT1-MMP (and possibly other proteins involved in invasion such as integrins) (38) from its intracellular reservoir in late endosomes to the cell surface, where it contributes to preparing the extracellular matrix for the invasion of the tumor cells. Consistent with this mechanism, our analysis of breast-tumor biopsies shows overexpression of both aPKCι and MT1-MMP in the most aggressive hormone receptor-negative HER2
+ and triple-negative subtypes. These proteins are found at cell-cell contacts and in intracellular vesicles in carcinoma cells, contrasting with their distinct locations on the apical and lateral plasma membranes, respectively, in healthy breast epithelial cells. The positive correlation between MT1-MMP and aPKCι mRNA expression in clinical samples was associated with poor prognosis, underscoring the functional importance of the kinase in progress of the disease.
The direct phosphorylation of cortactin residue S261 by aPKCι, as well as the association of aPKCι with cortactin-enriched domains on MT1-MMP-containing intracellular compartments, suggests that aPKCι phosphorylates cortactin on MT1-MMPcontaining late endosomes. The accumulation of hypophosphorylated cortactin in aPKCζ/ι-depleted cells or in the Ser261Ala mutant inhibited association of dyn-2 with cortactin-positive patches on MT1-MMP-containing endosomes, and it decreased matrix degradation. Based on the known function of dyn-2 in membrane scission on various compartments, including late endosomes (39), impaired dyn-2 recruitment onto MT1-MMPpositive late endosomes is probably responsible for the endosomal membrane tubulation we see, with adverse consequences for MT1-MMP delivery to the surface. Thus, our data reveal a role for aPKCζ/ι on late endocytic compartments and a previously unidentified mechanism of late endosome membrane remodeling based on cortactin phosphorylation by aPKC to control dyn-2 recruitment. Phosphorylation of S405 and S418 of cortactin by ERK1/2 also stimulates invadopodia formation and matrix degradation. In addition, phosphorylation of cortactin by ERK is involved in a recycling mechanism of internalized ECM components from late endosomes/lysosomes to promote cell motility (32) . However, our data indicate that ERK phosphorylation sites do not contribute to dyn-2 recruitment to cortactin-positive patches, thus suggesting different mechanisms of action for aPKCζ/ι and ERK-dependent phosphorylation sites for cortactin function during tumor-cell invasion.
Recent studies have documented an essential role for actin cytoskeleton dynamics in endosome function (30, 31, 40) . The mechanism emerging from these studies indicates that actin-Arp2/ 3 assemblies organize early endosomal membranes into functional subdomains and contribute to cargo sorting and generation of transport intermediates. Our observation that dynamic cortactinArp2/3-actin subdomains of MT1-MMP-containing multivesicular bodies coincide with sites of emergence and scission of tubulovesicular MT1-MMP carriers suggests a similar key role for actin in generating transport intermediates from multivesicular bodies/late endosomes. These mechanistic insights from cells in culture are consistent with our analysis of breast-tumor samples showing upregulation of both aPKCι and MT1-MMP associated with hormone receptor-negative aggressive breast tumors and with poor prognosis; patients whose tumors overexpressed both aPKCι and MT1-MMP had a significantly higher risk of metastasis. When taken together with the known implication of cortactin in cancer (41, 42) and the reported up-regulation of dyn-2 expression in human metastatic tumors (43) , our findings identify a key role for aPKCι, cortactin, dyn-2, and MT1-MMP in aggressive epithelial breast carcinomas and emphasize the role of polarity defects and endosomal transport in breast carcinogenesis, opening new avenues for innovative therapeutic strategies in aggressive forms of breast cancers.
The redistribution of aPKCι and MT1-MMP from the apical and lateral surfaces of epithelial cells, respectively, in normal mammary ducts to cell-cell contacts and vesicles-probably endosomes-in carcinoma cells correlates with the loss of epithelial-cell polarity observed in breast tumors. This redistribution seems particularly relevant in the context of tumor progression (see also ref. 44 ). Apical-basal polarity requires the activity of several proteins, including the apically located PAR complex, which contains aPKCζ/ι as well as CDC42, Par3, and Par6 (18) . Moreover, components of the PAR complex regulate vesicle transport in the endocytic pathway and play a critical role in the uptake and recycling of components required for epithelial integrity (45, 46) . Thus, our data suggest that a mechanism of endocytic recycling of specific cargoes based on aPKCζ/ι/cortactin/dyn-2 may operate in normal epithelial cells and may be required for maintenance of apicobasolateral polarity. Like aPKCι, Par6 is up-regulated in breast tumors (47) whereas loss of Par3 promotes breast-cancer metastasis (48, 49) . Collectively, these data suggest that deregulation of PAR complex components in breast carcinomas contributes to tumor progression via deregulation of cell polarity and that one major consequence of aPKCζ/ι overexpression and mislocalization in tumors is the recycling and exocytosis of MT1-MMP, promoting metastasis of carcinoma cells in most aggressive breast tumors.
Experimental Procedures
Antibodies and Plasmid Constructs. For antibodies and plasmid constructs, see SI Experimental Procedures.
Cell Culture, Transfection, Stable Cell Lines, and Knockdown. For cell culture, transfection, stable cell lines, and knockdown, see SI Experimental Procedures.
Fluorescent Gelatin Degradation Assay and Invasion Assays. Assays of fluorescent gelatin degradation were performed and quantified as previously described (15) . About 250-300 cells from at least three independent experiments were analyzed for each condition. Assays to measure cell invasion into Matrigel and to measure the invasion of cells from multicellular spheroids into native type I collagen assays were performed as described previously (13, 50) . The latter assays were quantified by estimating the diameter of spheroids at T0 and T2 as described (50) .
Indirect Immunofluorescence Microscopy, 3D Deconvolution, and Image Analysis. MDA-MB-231 cells were cultured on gelatin-coated coverslips and processed for immunofluorescence microscopy as previously described (13) . Image acquisition and analysis are described in SI Experimental Procedures.
Live-Cell Imaging and Analysis of MT1-MMP-Containing Endosome Movement. For live-cell imaging and analysis of MT1-MMP-containing endosome movement, see SI Experimental Procedures.
Total Interference Reflection Fluorescence Microscopy. Cells expressing MT1-MMP-mCherry and depleted of the proteins of interest (cortactin, aPKCζ/ι, dyn-2) by means of siRNAs were plated on cross-linked gelatin-coated glassbottom dishes (MatTek) for 2 h before imaging. TIRFM imaging was performed on a custom setup as described previously with a penetration depth of 150-300 nm (51) . MT1-MMP-mCherry at the cell surface was quantified by using integrated intensity measurement in Metamorph software. Statistical Analyses. Relationships between mRNA levels of various target genes and comparison of target-gene mRNA levels with clinical parameters were estimated by using the χ 2 test (for links between two qualitative parameters) and the Spearman rank correlation test (for links between two quantitative parameters). Differences between the two populations were judged significant at confidence levels greater than 95% (P < 0.05). Metastasis-free survival (MFS) was determined as the interval between diagnosis and detection of the first metastasis. Survival distributions were estimated by the Kaplan-Meier method, and the significance of differences between survival rates was ascertained using a log-rank test. Relationships between protein expression and distribution in tumors vs. normal adjacent tissues were estimated using the Kruskal-Wallis test (for links between qualitative and quantitative parameters). Other statistical analyses were performed using the ANOVA or Student t test (link between one qualitative parameter and one quantitative parameter) in Prism software.
